Phase 1b Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (ALK ) Gene Locus

Trial Profile

Phase 1b Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (ALK ) Gene Locus

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Nov 2017 Planned End Date changed from 1 Dec 2017 to 31 Jan 2018.
    • 08 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 08 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top